DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial
results for the quarter ended March 31, 2009.
Product revenue grew to approximately $2.7 million for the first quarter
of 2009, an increase of 46% from the $1.8 million in product revenue
reported for the first quarter of 2008, and an increase of approximately
8% from the $2.45 million reported for the fourth quarter of 2008. Total
first quarter 2009 revenue, which includes development grant revenue,
was $5.2 million, an increase of 180% from the same quarter in 2008, and
approximately 28% from the fourth quarter of 2008. The company reported
a net loss of $13.1 million or $0.33 per share for the first quarter of
2009, down from $13.8 million or $0.47 per share for the first quarter
of 2008. The net loss included $3.7 million in non-cash expenses during
the first quarter of 2009, which included $1.1 million in non-cash
interest expense associated with the adoption of FSP APB 14-1.
Cost of sales totaled $5.5 million for the first quarter of 2009,
compared to $3.2 million for the first quarter in 2008. The increase was
due to additional product sales and development costs related to
development and collaboration agreements entered into during 2008.
Research and development expense decreased by approximately $1.6 million
to $3.2 million for the first quarter of 2009, compared to $4.8 million
for the first quarter of 2008. The decrease in research and development
expense was primarily due to development and collaboration agreements
entered into during 2008 and the corresponding reclassification of
expenses to development cost of sales. Selling, general and
administrative expense increased by approximately $1.5 million to
$7.9 million for the first quarter of 2009, compared to $6.4 million for
the first quarter of 2008, with the change primarily due to additional
marketing and sales costs including increased consulting fees. As of
March 31, 2009, the Company had $65.2 million in cash, marketable
securities, and restricted cash.
Conference Call
Management will hold a conference call today starting at 4:30 pm
(Eastern Time). The conference call will be concurrently webcast. The
link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com
under the investor webcast section and will be archived for future
reference. To listen to the conference call, please dial (877) 856-1955
(US/Canada) or (719) 325-4804 (International) and use the participant
code "9211452" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and
marketing continuous glucose monitoring systems for ambulatory use by
patients and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history.
Successful commercialization and sale of the company’s products is
subject to numerous risks and uncertainties, including product
performance, a lack of acceptance in the marketplace by physicians and
patients, the company’s inability to manufacture products in commercial
quantities at an acceptable cost and quality level, possible delays in
the company’s development programs, the inability of patients to receive
reimbursements from third-party payors and inadequate financial and
other resources. Certain of these risks and uncertainties, in addition
to other risks, are more fully described in the company's quarterly
report on Form 10-Q for the period ending March 31, 2009, as filed with
the Securities and Exchange Commission on May 6, 2009.
|
DexCom, Inc.
|
|
Balance Sheets
|
|
(In thousands – except par value data)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
March 31,
2009
|
|
December 31,
2008 (1)
|
|
Assets
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
9,276
|
|
|
$
|
12,700
|
|
|
Short-term marketable securities, available-for-sale
|
|
|
52,176
|
|
|
|
14,368
|
|
|
Accounts receivable, net
|
|
|
1,345
|
|
|
|
1,118
|
|
|
Inventory
|
|
|
2,365
|
|
|
|
2,446
|
|
|
Prepaid and other current assets
|
|
|
1,344
|
|
|
|
1,426
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
66,506
|
|
|
|
32,058
|
|
|
Property and equipment, net
|
|
|
6,403
|
|
|
|
6,105
|
|
|
Restricted cash
|
|
|
3,702
|
|
|
|
4,270
|
|
|
Other assets
|
|
|
1,335
|
|
|
|
1,449
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
77,946
|
|
|
$
|
43,882
|
|
|
|
|
|
|
|
|
Liabilities and stockholders’ equity
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
3,774
|
|
|
$
|
4,599
|
|
|
Accrued payroll and related expenses
|
|
|
2,187
|
|
|
|
2,115
|
|
|
Current portion of long-term debt
|
|
|
1,588
|
|
|
|
1,931
|
|
|
Current portion of deferred revenue
|
|
|
7,448
|
|
|
|
6,351
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
14,997
|
|
|
|
14,996
|
|
|
Long-term portion of deferred revenue
|
|
|
4,173
|
|
|
|
5,669
|
|
|
Other liabilities
|
|
|
916
|
|
|
|
889
|
|
|
Long-term debt, net of current portion
|
|
|
42,706
|
|
|
|
41,796
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
62,792
|
|
|
|
63,350
|
|
|
Commitments and contingencies
|
|
|
|
|
|
Stockholders’ equity (deficit):
|
|
|
|
|
|
Preferred stock, $0.001 par value, 5,000 shares authorized; no
shares issued and outstanding at March 31, 2009 and December 31,
2008, respectively
|
|
|
—
|
|
|
|
—
|
|
|
Common stock, $0.001 par value, 100,000 authorized; 46,187 and
45,907 issued and outstanding at March 31, 2009; 30,103 and 29,824
shares issued and outstanding at December 31, 2008
|
|
|
46
|
|
|
|
30
|
|
|
Additional paid-in capital
|
|
|
265,921
|
|
|
|
218,136
|
|
|
Accumulated other comprehensive income
|
|
|
13
|
|
|
|
50
|
|
|
Accumulated deficit
|
|
|
(250,826
|
)
|
|
|
(237,684
|
)
|
|
|
|
|
|
|
|
Total stockholders’ equity (deficit)
|
|
|
15,154
|
|
|
|
(19,468
|
)
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity (deficit)
|
|
$
|
77,946
|
|
|
$
|
43,882
|
|
|
|
|
|
|
|
|
(1) The Consolidated Balance Sheet at December 31, 2008 has been
derived from the audited consolidated financial statements as
adjusted for the adoption of FSP APB 14-1.
|
|
|
|
|
|
DexCom, Inc.
|
|
Statements of Operations
|
|
(In thousands – except per share data)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
|
2009
|
|
|
|
2008 (1)
|
|
Product revenue
|
|
$
|
2,672
|
|
|
$
|
1,824
|
|
|
Development grant revenue
|
|
|
2,540
|
|
|
|
38
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
5,212
|
|
|
|
1,862
|
|
|
Product cost of sales
|
|
|
3,522
|
|
|
|
3,112
|
|
|
Development cost of sales
|
|
|
1,953
|
|
|
|
130
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
|
5,475
|
|
|
|
3,242
|
|
|
|
|
|
|
|
|
Gross margin (deficit)
|
|
|
(263
|
)
|
|
|
(1,380
|
)
|
|
Operating expenses
|
|
|
|
|
|
Research and development
|
|
|
3,171
|
|
|
|
4,843
|
|
|
Selling, general and administrative
|
|
|
7,903
|
|
|
|
6,421
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
11,074
|
|
|
|
11,264
|
|
|
Operating loss
|
|
|
(11,337
|
)
|
|
|
(12,644
|
)
|
|
Interest income
|
|
|
123
|
|
|
|
565
|
|
|
Interest expense
|
|
|
(1,928
|
)
|
|
|
(1,735
|
)
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(13,142
|
)
|
|
$
|
(13,814
|
)
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(0.33
|
)
|
|
$
|
(0.47
|
)
|
|
|
|
|
|
|
|
Shares used to compute basic and diluted net loss per share
|
|
|
39,569
|
|
|
|
29,228
|
|
|
|
|
|
|
|
|
(1) Adjusted for the required retrospective application of FSP APB
14-1.
|
DexCom, Inc.
Steve Pacelli, Chief Administrative Officer
858-200-0200
www.dexcom.com
